Product Images Ticagrelor

This appears to be data from a study comparing the response rate of patients with athersclerosis who were treated with either clopidogrel or a placebo. The data shows the percentage of patients who experienced a cardiovascular event at 12 months, with significantly fewer events reported in the clopidogrel group. The remaining text appears to be values for different time points and dosages, but it is not clear what specific values they represent.*

The provided text appears to be a statistical report of a medical study, showing the number and percentage of patients with a certain condition, and the outcome for those patients using different treatments. Unfortunately, without knowing the specific condition, treatments, and other relevant information, it's difficult to provide more specific information.*

This is a table that shows the cumulative percentage over time for two treatments, Ticagrelor and Placebo, along with the number of patients in the study. The table contains data for different months following randomization, but the purpose of the study is not mentioned.*

This is a medication guide for Ticagrelor tablets. Each film-coated tablet contains 90 mg ticagrelor. The recommended adult dosage should be checked on the package insert. The medication should be stored at a temperature between 20" to 25°C (68" to 77°F) and kept out of the reach of children. The manufacturer is Amneal Pharmaceuticals Pvt. Ltd. based in Ahmedabad, India and distributed by Amneal Pharmaceuticals LLC in Bridgewater, NJ.*

Ticagrelor 180 mg and Clopidogrel 600 mg are medications commonly used to prevent blood clots. The remaining text is not readable and appears to be an error in the .*

This text provides medical recommendations for Ticagrelor (AR-C124910) dosages and adjustments based on intrinsic factors such as age, gender, ethnicity, and renal/hepatic impairment. However, Ticagrelor has not been studied in patients with moderate or severe hepatic impairment. Change relative to reference is graphed on a chart.*

This text seems to be a chart or a table listing different medications and their recommendations while interacting with Ticagrelor AR-C124910XX drug. The recommendations are categorized as Strong CYP3A inhibitors, Moderate CYP3A4 inhibitors, Potent CYP3A4 inducers, and P-gP and CYP3A inhibitors. The chart provides information on possible dose adjustments and changes relative to reference PK regarding the interacting drugs. Additionally, the text mentions to see Dosage and Administration (2) section for more information.*

This text provides a chart about the interacting drug effects of ticagrelor with various other drugs such as simvastatin, atorvastatin, and digoxin. It also gives recommendations for dose adjustments and monitoring digoxin levels when starting or changing ticagrelor therapy.*